Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2002 1
2003 3
2004 6
2005 2
2006 8
2007 6
2008 7
2009 8
2010 8
2011 10
2012 11
2013 9
2014 10
2015 8
2016 13
2017 20
2018 17
2019 10
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Results by year

Filters applied: . Clear all
Page 1
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators. Maurer MS, et al. N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27. N Engl J Med. 2018. PMID: 30145929 Free article. Clinical Trial.
Reply.
Reynolds MM, Veverka KK, Gertz MA, Dispenzieri A, Zeldenrust SR, Leung N, Pulido JS. Reynolds MM, et al. Among authors: zeldenrust sr. Am J Ophthalmol. 2018 Feb;186:170. doi: 10.1016/j.ajo.2017.11.005. Epub 2017 Dec 13. Am J Ophthalmol. 2018. PMID: 29248199 No abstract available.
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T; patisiran Global OLE study group. Adams D, et al. Lancet Neurol. 2021 Jan;20(1):49-59. doi: 10.1016/S1474-4422(20)30368-9. Epub 2020 Nov 16. Lancet Neurol. 2021. PMID: 33212063 Clinical Trial.
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.
Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA. Kumar S, et al. Among authors: zeldenrust sr. J Clin Oncol. 2012 Mar 20;30(9):989-95. doi: 10.1200/JCO.2011.38.5724. Epub 2012 Feb 13. J Clin Oncol. 2012. PMID: 22331953 Free PMC article.
OCULAR MANIFESTATIONS OF SYSTEMIC AMYLOIDOSIS.
Reynolds MM, Veverka KK, Gertz MA, Dispenzieri A, Zeldenrust SR, Leung N, Pulido JS. Reynolds MM, et al. Among authors: zeldenrust sr. Retina. 2018 Jul;38(7):1371-1376. doi: 10.1097/IAE.0000000000001901. Retina. 2018. PMID: 29068915
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.
Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves WI, Hayman SR, Kapoor P, Kourelis T, Kumar SK, Kyle RA, Lacy MQ, Leung N, Lin Y, Lust JA, Mikhael JR, Reeder CB, Roy V, Russell SJ, Sher T, Stewart AK, Warsame R, Zeldenrust SR, Rajkumar SV, Chanan Khan AA. Dingli D, et al. Among authors: zeldenrust sr. Mayo Clin Proc. 2017 Apr;92(4):578-598. doi: 10.1016/j.mayocp.2017.01.003. Epub 2017 Mar 11. Mayo Clin Proc. 2017. PMID: 28291589 Free PMC article. Review.
Smoldering multiple myeloma requiring treatment: time for a new definition?
Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, Kumar SK. Dispenzieri A, et al. Among authors: zeldenrust sr. Blood. 2013 Dec 19;122(26):4172-81. doi: 10.1182/blood-2013-08-520890. Epub 2013 Oct 21. Blood. 2013. PMID: 24144641 Free PMC article. Review.
Natural history of t(11;14) multiple myeloma.
Lakshman A, Alhaj Moustafa M, Rajkumar SV, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Lakshman A, et al. Among authors: zeldenrust sr. Leukemia. 2018 Jan;32(1):131-138. doi: 10.1038/leu.2017.204. Epub 2017 Jun 27. Leukemia. 2018. PMID: 28655925
Impact of acquired del(17p) in multiple myeloma.
Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Lakshman A, et al. Among authors: zeldenrust sr. Blood Adv. 2019 Jul 9;3(13):1930-1938. doi: 10.1182/bloodadvances.2018028530. Blood Adv. 2019. PMID: 31248884 Free PMC article.
136 results